Professor Gavin Giovannoni
Treating MS beyond no evident inflammatory activity (NEIDA): why AHSCT should be an option available to people with MS
It is becoming increasingly clear that many patients rendered free of focal inflammatory disease activity (relapses and MRI activity) continue to worsen due to smouldering MS. However, early immune reconstitution therapies, including AHSCT, may prevent smouldering MS.
In his talk, Treating MS beyond no evident inflammatory activity (NEIDA): why AHSCT should be an option available to people with MS, Professor Giovannoni will discuss smouldering MS, the Epstein-Barr virus's role in the disease, and how AHSCT and evolving therapies may address smouldering MS.
Prof. Giovannoni is speaking at this event to help the AIMS Charity raise awareness about AHSCT and to nudge the MS community towards adopting AHSCT as a treatment option for people with MS and to end the disparities that exist in the NHS regarding access to AHSCT.
It is becoming increasingly clear that many patients rendered free of focal inflammatory disease activity (relapses and MRI activity) continue to worsen due to smouldering MS. However, early immune reconstitution therapies, including AHSCT, may prevent smouldering MS.
In his talk, Treating MS beyond no evident inflammatory activity (NEIDA): why AHSCT should be an option available to people with MS, Professor Giovannoni will discuss smouldering MS, the Epstein-Barr virus's role in the disease, and how AHSCT and evolving therapies may address smouldering MS.
Prof. Giovannoni is speaking at this event to help the AIMS Charity raise awareness about AHSCT and to nudge the MS community towards adopting AHSCT as a treatment option for people with MS and to end the disparities that exist in the NHS regarding access to AHSCT.
It is becoming increasingly clear that many patients rendered free of focal inflammatory disease activity (relapses and MRI activity) continue to worsen due to smouldering MS. However, early immune reconstitution therapies, including AHSCT, may prevent smouldering MS.
In his talk, Treating MS beyond no evident inflammatory activity (NEIDA): why AHSCT should be an option available to people with MS, Professor Giovannoni will discuss smouldering MS, the Epstein-Barr virus's role in the disease, and how AHSCT and evolving therapies may address smouldering MS.
Prof. Giovannoni is speaking at this event to help the AIMS Charity raise awareness about AHSCT and to nudge the MS community towards adopting AHSCT as a treatment option for people with MS and to end the disparities that exist in the NHS regarding access to AHSCT.